VE303
- Generic Name
- VE303
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
VE303 is under clinical development by Vedanta Biosciences.
- Associated Conditions
- -
- Associated Therapies
- -
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Phase 3
Recruiting
- Conditions
- Clostridioides Difficile Infection RecurrenceDiarrhea InfectiousClostridium DifficileClostridium Difficile Infection RecurrenceC.Difficile DiarrheaClostridioides Difficile InfectionClostridium Difficile InfectionsC. Diff InfectionRecurrent Clostridium Difficile InfectionCDI
- Interventions
- Biological: PlaceboBiological: VE303
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Vedanta Biosciences, Inc.
- Target Recruit Count
- 852
- Registration Number
- NCT06237452
- Locations
- 🇧🇬
UMHAT Burgas AD, Burgas, Bulgaria
🇧🇬MBAL Dr. Ivan Seliminski - Sliven AD, Sliven, Bulgaria
🇮🇹AOU Pisana - Stabilimento di Cisanello, Pisa, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath